A phase 2 clinical trial was conducted on 30 male Fragile X patients who were administered an inhibitor of phosphodiesterase 4 (PDE4) in order to enhance cAMP signaling (which is depressed in Fragile X Syndrome); results from this study show an improvement in cognition, language and daily functioning [105]. The gene discussed is PDE4A; the disease is fragile X syndrome.